Careers  |  Sign In  |  Register  |   Twitter

Potential New Treatment for People With Asthma

A new study in The New England Journal of Medicine evaluates the efficacy of dupilumab, a drug being developed by Sanofi and Regeneron Pharmaceuticals, in patients with persistent, moderate-to-severe asthma and elevated eosinophil levels. “Three patients had an asthma exacerbation with dupilumab (6%) versus 23 with placebo (44%), corresponding to an 87% reduction with dupilumab (odds ratio, 0.08; 95% confidence interval, 0.02 to 0.28; P<0.001). Significant improvements were observed for most measures of lung function and asthma control.”

Read it in NEJM.